Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460)
:0460
Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$1.50
▲(13.64% Upside)
Action:UpgradedDate:01/27/26
The score is held back primarily by weak financial performance—declining revenue, ongoing losses, and unstable/negative free cash flow. Technicals are comparatively stronger with price above major moving averages and a positive MACD, but RSI near 70 indicates momentum may be stretched. Valuation is also constrained by the loss-making profile despite a high dividend yield.
Positive Factors
Therapeutic diversification & proprietary drugs
Broad exposure across cardiovascular, CNS and anti-infection markets plus proprietary products reduces single-product risk and supports multiple revenue streams. This durable portfolio mix helps steady revenue when individual drug lifecycles fluctuate and aids long-term commercialization potential.
Negative Factors
Multi-year revenue decline
A sustained fall in top-line over several years signals weakening market share, potential product obsolescence, or commercialization gaps. That trend undermines scale economics, strains R&D payback, and makes profitable growth harder absent successful new launches or market re-expansion initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Therapeutic diversification & proprietary drugs
Broad exposure across cardiovascular, CNS and anti-infection markets plus proprietary products reduces single-product risk and supports multiple revenue streams. This durable portfolio mix helps steady revenue when individual drug lifecycles fluctuate and aids long-term commercialization potential.
Read all positive factors
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.16B
Dividend Yield0.87%
Average Volume (3M)37.54M
Price to Earnings (P/E)22.8
Beta (1Y)1.03
Revenue Growth19.21%
EPS Growth-115.91%
CountryHK
Employees2,667
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding9,329,999,000
10 Day Avg. Volume24,963,024
30 Day Avg. Volume37,542,935
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)1.31
Price to Sales (P/S)3.02
P/FCF Ratio99.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$3.39B
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Company Description
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, meta...
How the Company Makes Money
Sihuan Pharmaceutical generates revenue through the sale of its pharmaceutical products, which are distributed to hospitals, clinics, and pharmacies across China and other markets. The company has several key revenue streams including prescription...
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10B | 1.90B | 1.86B | 2.18B | 3.04B | 2.46B |
| Gross Profit | 1.39B | 1.24B | 1.30B | 1.49B | 2.43B | 1.91B |
| EBITDA | -18.36M | -208.66M | 334.31M | -1.54B | 931.69M | 714.06M |
| Net Income | -80.64M | -216.66M | -54.02M | -1.91B | 416.51M | 473.38M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 10.53B | 11.54B | 12.14B | 14.50B | 13.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.63B | 4.48B | 4.79B | 5.79B | 4.94B |
| Total Debt | 1.03B | 942.76M | 1.26B | 1.29B | 1.08B | 755.05M |
| Total Liabilities | 5.68B | 5.58B | 6.40B | 6.50B | 5.35B | 3.10B |
| Stockholders Equity | 4.38B | 4.37B | 4.43B | 4.74B | 8.28B | 9.19B |
Cash Flow | ||||||
| Free Cash Flow | 62.70M | 57.51M | -95.93M | -355.97M | 64.28M | -279.51M |
| Operating Cash Flow | 112.15M | 243.89M | 199.49M | 46.49M | 665.29M | 227.13M |
| Investing Cash Flow | 368.40M | 758.24M | 169.88M | -1.66B | -337.57M | -924.78M |
| Financing Cash Flow | -1.23B | -1.26B | -419.56M | -238.93M | 750.66M | 184.54M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Positive
1.32
Price Trends
1.48
Negative
1.40
Positive
1.41
Negative
Market Momentum
-0.03
Negative
49.72
Neutral
74.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Positive. The current price of 1.32 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.48, and below the 200-day MA of 1.41, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 74.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0460.
Sihuan Pharmaceutical Holdings Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$14.03B | 5.21 | 24.04% | 3.93% | 19.05% | 13.68% | |
58 Neutral | HK$9.64B | 14.45 | 7.49% | 4.47% | 1.65% | -16.38% | |
54 Neutral | HK$9.06B | -28.37 | -1.64% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.16B | 22.81 | -1.84% | 0.87% | 19.21% | -115.91% | |
47 Neutral | HK$13.10B | 292.71 | 0.57% | ― | 29.21% | 80.37% |
* Healthcare Sector Average
HK:0460
Sihuan Pharmaceutical Holdings Group
1.41
0.84
149.12%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.80
-0.03
-1.48%
HK:1681
Consun Pharmaceutical Group Ltd.
17.07
8.90
108.96%
HK:6185
CanSino Biologics, Inc. Class H
33.04
5.84
21.47%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.40
1.37
27.29%
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications
Jan 16, 2026
Sihuan Pharmaceutical announced that its subsidiary Meiyan Space Biotechnology has received National Medical Products Administration approval in China for six new specifications of its polylactic acid (PLLA) facial filler, adding 60mg to 130mg for...
Sihuan Pharmaceutical Launches Share Buyback Amid Pivotal Turnaround and Aesthetics-Led Growth
Dec 29, 2025
Sihuan Pharmaceutical has launched a share repurchase program under its existing mandate, buying back 8 million shares on the market at an average price of HK$1.2511 per share, equivalent to about 0.0874% of its issued share capital, with plans to...
Sihuan Pharma Buys 9 Million Shares for Award Scheme as Dual-Drive Strategy Advances
Dec 18, 2025
Sihuan Pharmaceutical Holdings Group has disclosed that the trustee of its 2022 share award scheme purchased 9 million shares on the market on 18 December 2025, representing about 0.0983% of its issued share capital, at an average price of roughly...
Sihuan Pharmaceutical’s Anjiuwei Secures Spot in 2025 NRDL, Boosting Market Prospects
Dec 8, 2025
Sihuan Pharmaceutical Holdings Group announced the successful renewal and inclusion of its innovative drug, Anjiuwei, in the 2025 National Reimbursement Drug List (NRDL) in China. This renewal is expected to stabilize market sales and enhance the ...
Sihuan Pharmaceutical’s Innovative Drug Xuanyuening Gains NRDL Inclusion
Dec 8, 2025
Sihuan Pharmaceutical Holdings Group Ltd. announced that its innovative drug, Bireociclib Tablets (brand name: Xuanyuening), developed by its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been included in the National Reimbursement Drug List...
Sihuan Pharmaceutical’s Xuanzhu Biopharma Plans H Share Full Circulation
Nov 18, 2025
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharma, is considering the implementation of H share full circulation. This involves converting approximately 68.97% of its unlisted shares into H shares, pending ...
Sihuan Pharmaceutical Partners with Abalone Bio for Innovative Obesity Therapy
Oct 30, 2025
Sihuan Pharmaceutical Holdings Group Ltd. has signed a cooperation agreement with U.S.-based Abalone Bio to jointly develop a new-generation innovative therapy for weight loss and muscle gain. This collaboration aims to advance research in targeti...
Sihuan Pharmaceutical’s NG-350A Receives FDA Fast Track Designation
Oct 28, 2025
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharm, has received Fast Track designation from the U.S. FDA for NG-350A, a treatment for mismatch repair-proficient locally advanced rectal cancer. This designati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.